Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of
the oral Janus kinase (JAK) 1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian …

Baricitinib (also known as LY3009104 or INCB028050), a novel and potent small molecule
inhibitor of Janus kinase family of enzymes (JAKs) with selectivity for JAK1 and JAK2, is …

BACKGROUND. Monogenic IFN–mediated autoinflammatory diseases present in infancy
with systemic inflammation, an IFN response gene signature, inflammatory organ damage …

Janus kinase (JAK) is a signal transducer and activator of a protein transcription system that
transduces signals from cell surface cytokine and growth factor receptors to the nucleus …

Background ABT-494 is a potent and selective Janus kinase (JAK) 1 inhibitor being
developed for the treatment of several autoimmune disorders, with potential for an improved …

Abstract Purpose of Review Given the recent increase in the profile and use of Janus kinase
inhibitors (JAKinibs) in adult patients with rheumatic diseases, we aimed to review the …

Janus kinase (JAK) inhibitors (jakinibs) that target downstream signalling by a large range of
cytokines are effective in treating autoimmune and rheumatic diseases. Newer jakinibs that …

Objective This study aimed to assess the efficacy and safety of 2 Janus kinase (JAK)
inhibitors (jakinibs) tofacitinib and ruxolitinib in the treatment of type I interferonopathies …

Janus kinase (JAK) inhibitors have emerged as an effective class of therapies for various
inflammatory diseases such as rheumatoid arthritis (RA). JAK inhibitors function …

Pharmacological modulation of the Janus kinase (JAK) family has achieved clinically
meaningful therapeutic outcomes for the treatment of inflammatory and hematopoietic …